Moteur de recherche d’entreprises européennes
Financement de l’UE (2 999 999 €) : Développement d’amplificateurs « intelligents » d’espèces réactives de l’oxygène spécifiques aux polynucléaires aberrants neutrophiles pour le traitement des … Hor04/09/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Développement d’amplificateurs « intelligents » d’espèces réactives de l’oxygène spécifiques aux polynucléaires aberrants neutrophiles pour le traitement des maladies inflammatoires et auto-immunes, du cancer et de la myéloablation.
Reactive oxygen species (ROS) have key functions in healthy organism such as redox signaling for regulation of cell growth, triggering formation of neutrophil extracellular traps (NETs), and modulation of inflammation. Since in high concentration ROS are damaging to tissues, nature has evolved precise mechanisms to control their generation at the required time, concentration and space, proximal to their target. Disturbance of these mechanisms leads to aberrant ROS production that causes uncontrolled inflammation, occurs in myeloablation caused by radio- or chemotherapy and is a crucial feature of cancer cell phenotype as well as autoimmunity. Despite the damaging properties of ROS it is a paradox that pharmaceutical ROS amplifiers can reverse (“cure”) many pathologic features. For example, ROS-induced cancer cell killing inhibits cancer growth, ROS-induced deactivation of T-cells and NETs generation contributes to resolution of inflammation, and ROS-induced boosting of haematopoiesis can relieve myeloablation. These exciting possibilities have not been realized in clinical settings yet, since the high level of temporal and spatial control of ROS generation, required to allow for safe patient treatment, has yet not been achieved for any known drug. NeutroCure will be the first attempt to achieve a breakthrough solution to this problem. Using an innovative approach based on the multiple-trigger prodrug activation, this consortium will develop safe ROS amplifiers capable of boosting ROS specifically in abnormal polymorphonuclear neutrophils associated with cancer, uncontrolled inflammation and relevant for myeloablation without affecting normal cells. NeutroCure consists of 6 European academic partners and an SME who will promote commercialization of the new drugs. We expect that this project will have a great positive impact on the Society by providing previously unexplored treatment solutions for severe pathological conditions caused by dysregulated ROS-production.
| Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) | 400 000 € |
| FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG | 629 000 € |
| Institute OF Cellular Biology And Pathology 'Nicolae Simionescu' - Romanian Academy | 215 648 € |
| Institut Gustave Roussy | 120 000 € |
| Institut National de la Sante et de la Recherche Medicale | 0,00 € |
| Lvivskyi Nationalnyi Medychnyi Universytet Imeni Danyla Halytskoho | 184 352 € |
| Pronoxis AB | 0,00 € |
| Redoxis AB | 400 000 € |
| Swansea University | 410 999 € |
| UNIVERSITAET zu LUEBECK | 0,00 € |
| UNIVERSITATSKLINIKUM ERLANGEN | 547 054 € |
| UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN | 92 946 € |
| University of Surrey | 0,00 € |
https://cordis.europa.eu/project/id/861878
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.